Novo set out its 2030 strategic ambitions at a Capital Markets Day in London on Monday, but the plan failed to satisfy investors hoping for a more decisive turnaround, sending the company's stock down as much as 7% before paring losses to 5.4% by midday in Copenhagen. At the event, the company outlined targets to bring more than five drugs with multi-blockbuster potential to market by 2030, reach over 150 billion Danish kroner ($23 billion) in risk-adjusted pipeline sales by 2035, and expand revenue from 2026 to 2030 at a pace consistent with industry peers.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.